TMDX
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 7.14 · operating margin 18%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 1 336 titres (~109 057,68 $ US)
- Insiders
- Weill David
- Total bought
-
$109,058
Avg buy (VWAP, 90d window) $81.63 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-11
- Last synced
-
2026-09-17 09:54:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Weill David | Buy | 1,336 | $81.63 | $109,058 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-16
TMDX exhibits exceptional financial health with strong profitability, liquidity, and operational momentum (scores 90/85), but the catalytic signal is materially weakened by a low-conviction insider cluster (single…
The first sentence of the analysis written for TMDX on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 59.9% | 59.4% | 63.8% | 69.8% | 69.9% | |
| Ebit Margin | 20.0% | 11.4% | -6.6% | -34.7% | -133.2% | |
| Ebitda Margin | 24.5% | 15.8% | -3.2% | -31.0% | -127.2% | |
| Operating Profit Margin | 17.9% | 8.5% | -11.9% | -33.6% | -130.3% | |
| Pretax Profit Margin | 17.8% | 8.1% | -11.0% | -38.7% | -146.0% | |
| Continuous Operations Profit Margin | 31.4% | 8.0% | -10.4% | -38.8% | -146.1% | |
| Net Profit Margin | 31.4% | 8.0% | -10.4% | -38.8% | -146.1% | |
| Bottom Line Profit Margin | 31.4% | 8.0% | -10.4% | -38.8% | -146.1% | |
| Current Ratio | 7.142 | 8.299 | 9.296 | 10.663 | 5.108 | |
| Quick Ratio | 6.594 | 7.522 | 8.491 | 9.792 | 4.469 | |
| Solvency Ratio | 0.365 | 0.096 | -0.030 | -0.365 | -0.632 | |
| Cash Ratio | 5.469 | 5.619 | 7.187 | 8.503 | 1.101 | |
| Price To Earnings Ratio | 21.723 | 58.271 | -102.506 | -50.179 | -11.975 | |
| Price To Earnings Growth Ratio | 0.051 | -0.244 | 2.741 | 2.170 | -0.316 | |
| Forward Price To Earnings Growth Ratio | 0.051 | -0.244 | 2.741 | 2.170 | -0.316 | |
| Price To Earnings Diluted Ratio | 24.979 | 61.733 | -102.506 | -50.179 | -11.975 | |
| Price To Earnings Diluted Growth Ratio | 0.065 | -0.267 | 2.741 | 2.170 | -0.316 | |
| Price To Book Ratio | 8.741 | 9.063 | 18.707 | 9.736 | 7.798 | |
| Price To Sales Ratio | 6.830 | 4.692 | 10.622 | 19.519 | 17.485 | |
| Price To Free Cash Flow Ratio | 30.955 | -25.598 | -13.362 | -31.603 | -16.340 | |
| Price To Operating Cash Flow Ratio | 21.444 | 42.454 | -197.006 | -39.816 | -18.332 | |
| Debt To Assets Ratio | 0.440 | 0.645 | 0.731 | 0.244 | 0.325 | |
| Debt To Equity Ratio | 0.993 | 2.267 | 3.760 | 0.361 | 0.646 | |
| Debt To Capital Ratio | 0.498 | 0.694 | 0.790 | 0.265 | 0.392 | |
| Long Term Debt To Capital Ratio | 0.491 | 0.690 | 0.787 | 0.239 | 0.342 | |
| Financial Leverage Ratio | 2.258 | 3.517 | 5.146 | 1.479 | 1.988 | |
| Working Capital Turnover Ratio | 1.228 | 0.989 | 0.706 | 0.577 | 0.263 | |
| Operating Cash Flow Ratio | 2.159 | 0.815 | -0.237 | -1.936 | -1.242 | |
| Operating Cash Flow Sales Ratio | 0.318 | 0.111 | -0.054 | -0.490 | -0.954 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.693 | -1.659 | 14.744 | 1.260 | 1.122 | |
| Debt Service Coverage Ratio | 8.536 | 4.063 | -0.562 | -7.790 | -9.944 | |
| Interest Coverage Ratio | 7.879 | 2.602 | -2.662 | -8.437 | -10.178 | |
| Short Term Operating Cash Flow Coverage Ratio | 14.488 | 17.896 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.411 | 0.094 | -0.025 | -0.678 | -0.659 | |
| Capital Expenditure Coverage Ratio | 3.255 | 0.376 | -0.073 | -3.848 | -8.202 | |
| Dividend Paid And Capex Coverage Ratio | 3.255 | 0.376 | -0.073 | -3.848 | -8.202 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 27.723 | 32.218 | -348.920 | -58.375 | -14.222 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 59.9% | ▲0.6% | ▼-4.6% |
| Ebit Margin | 20.0% | ▲8.7% | ▲48.6% |
| Ebitda Margin | 24.5% | ▲8.7% | ▲48.7% |
| Operating Profit Margin | 17.9% | ▲9.4% | ▲47.8% |
| Pretax Profit Margin | 17.8% | ▲9.7% | ▲51.7% |
| Continuous Operations Profit Margin | 31.4% | ▲23.4% | ▲62.6% |
| Net Profit Margin | 31.4% | ▲23.4% | ▲62.6% |
| Bottom Line Profit Margin | 31.4% | ▲23.4% | ▲62.6% |
| Current Ratio | 7.142 | ▼-1.157 | ▼-0.960 |
| Quick Ratio | 6.594 | ▼-0.928 | ▼-0.779 |
| Solvency Ratio | 0.365 | ▲0.269 | ▲0.478 |
| Cash Ratio | 5.468 | ▼-0.150 | ▼-0.107 |
| Price To Earnings Ratio | 21.723 | ▼-36.548 | ▲38.656 |
| Price To Earnings Growth Ratio | 0.051 | ▲0.295 | ▼-0.829 |
| Forward Price To Earnings Growth Ratio | 0.051 | ▲0.295 | ▼-0.829 |
| Price To Earnings Diluted Ratio | 24.980 | ▼-36.753 | ▲40.569 |
| Price To Earnings Diluted Growth Ratio | 0.065 | ▲0.332 | ▼-0.813 |
| Price To Book Ratio | 8.741 | ▼-0.322 | ▼-2.068 |
| Price To Sales Ratio | 6.830 | ▲2.137 | ▼-5.000 |
| Price To Free Cash Flow Ratio | 30.955 | ▲56.553 | ▲42.145 |
| Price To Operating Cash Flow Ratio | 21.444 | ▼-21.010 | ▲59.695 |
| Debt To Assets Ratio | 0.440 | ▼-0.205 | ▼-0.037 |
| Debt To Equity Ratio | 0.993 | ▼-1.274 | ▼-0.613 |
| Debt To Capital Ratio | 0.498 | ▼-0.196 | ▼-0.030 |
| Long Term Debt To Capital Ratio | 0.491 | ▼-0.199 | ▼-0.019 |
| Financial Leverage Ratio | 2.258 | ▼-1.259 | ▼-0.620 |
| Working Capital Turnover Ratio | 1.228 | ▲0.240 | ▲0.476 |
| Operating Cash Flow Ratio | 2.159 | ▲1.345 | ▲2.248 |
| Operating Cash Flow Sales Ratio | 0.319 | ▲0.208 | ▲0.532 |
| Free Cash Flow Operating Cash Flow Ratio | 0.693 | ▲2.351 | ▼-2.539 |
| Debt Service Coverage Ratio | 8.536 | ▲4.473 | ▲9.675 |
| Interest Coverage Ratio | 7.879 | ▲5.276 | ▲10.038 |
| Short Term Operating Cash Flow Coverage Ratio | 14.488 | ▼-3.408 | ▲8.011 |
| Operating Cash Flow Coverage Ratio | 0.411 | ▲0.316 | ▲0.582 |
| Capital Expenditure Coverage Ratio | 3.255 | ▲2.878 | ▲4.953 |
| Dividend Paid And Capex Coverage Ratio | 3.255 | ▲2.878 | ▲4.953 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 27.724 | ▼-4.494 | ▲100.039 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.14B | $2.07B | $2.57B | $1.82B | $529.1M | |
| Enterprise value | $4.12B | $2.25B | $2.69B | $1.69B | $547.4M | |
| EV / Sales | 6.80x | 5.10x | 11.12x | 18.09x | 18.09x | |
| EV / Op. cash flow | 21.35x | 46.18x | -206.30x | -36.90x | -18.96x | |
| EV / Free cash flow | 30.82x | -27.84x | -13.99x | -29.29x | -16.90x | |
| EV / EBITDA | 27.72x | 32.22x | -348.92x | -58.38x | -14.22x | |
| Net debt / EBITDA | -0.13x | 2.60x | -15.73x | 4.61x | -0.47x | |
| Current ratio | 7.14x | 8.30x | 9.30x | 10.66x | 5.11x | |
| Income quality | 1.01x | 1.38x | 0.52x | 1.26x | 0.65x | |
| Graham number | $42 | $13 | — | — | — | |
| Graham net-net | -$1 | -$4 | -$3 | $5 | $1 | |
| Tax burden | 177.0% | 99.1% | 93.8% | 100.2% | 100.1% | |
| Interest burden | 88.6% | 71.3% | 168.0% | 111.5% | 109.6% | |
| Working capital | $548.5M | $437.3M | $455.7M | $228.6M | $95.5M | |
| Invested capital | $894.8M | $743.5M | $650.6M | $253.0M | $111.2M | |
| Return on assets | 17.8% | 4.4% | -3.5% | -13.1% | -32.8% | |
| Operating ROA | 11.6% | 5.0% | -5.8% | -15.3% | -27.5% | |
| Return on tangible assets | 18.0% | 4.5% | -3.6% | -13.1% | -32.8% | |
| Return on equity | 40.2% | 15.5% | -18.2% | -19.3% | -65.2% | |
| Return on invested capital | 10.9% | 5.0% | -4.1% | -12.3% | -35.3% | |
| Return on capital employed | 11.1% | 5.0% | -4.4% | -12.4% | -35.3% | |
| Earnings yield | 4.6% | 1.7% | -1.0% | -2.0% | -8.4% | |
| Free cash flow yield | 3.2% | -3.9% | -7.5% | -3.2% | -6.1% | |
| Capex / Op. cash flow | 30.7% | 265.9% | -1374.4% | -26.0% | -12.2% | |
| Capex / Depreciation | 218.0% | 656.7% | 2189.8% | 342.4% | 193.7% | |
| Capex / Sales | 9.8% | 29.4% | 74.1% | 12.7% | 11.6% | |
| SG&A / Sales | 30.6% | 38.2% | 49.5% | 74.8% | 126.5% | |
| R&D / Sales | 11.4% | 12.7% | 26.2% | 28.7% | 73.7% | |
| Stock comp / Sales | 6.1% | 7.5% | 8.2% | 11.0% | 22.7% | |
| Intangibles / Total assets | 1.3% | 1.7% | 2.0% | 0.0% | 0.0% | |
| Days sales outstanding | 51d | 81d | 96d | 108d | 72d | |
| Days payables outstanding | 16d | 21d | 53d | 43d | 267d | |
| Operating cycle | 124d | 175d | 280d | 375d | 667d | |
| Cash conversion cycle | 109d | 155d | 227d | 331d | 401d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+99.6%EV / Sales ▲+33.2%EV / EBITDA ▼-13.9%EV / Op. cash flow ▼-24.829Earnings yield ▲+0.029Graham number ▲+29.015
Profitability
Return on equity ▲+0.247Return on assets ▲+0.134Return on invested capital ▲+0.060Return on capital employed ▲+0.061Operating ROA ▲+0.066Income quality ▼-0.363Tax burden ▲+0.779
Efficiency
Days sales outstanding ▼-29.976Days payables outstanding ▼-5.367Operating cycle ▼-51.145Cash conversion cycle ▼-45.779Capex / Sales ▼-0.196R&D / Sales ▼-0.013
Balance-sheet strength
Current ratio ▼-1.157Net debt / EBITDA ▼-2.723Working capital ▲+111175000.000Invested capital ▲+151331000.000Intangibles / Total assets ▼-0.004
Change over 5 years
Valuation
Market cap ▲+681.5%EV / Sales ▼-62.4%EV / EBITDA ▲+294.9%EV / Op. cash flow ▲+40.311Earnings yield ▲+0.130
Profitability
Return on equity ▲+1.054Return on assets ▲+0.506Return on invested capital ▲+0.463Return on capital employed ▲+0.464Operating ROA ▲+0.391Income quality ▲+0.361Tax burden ▲+0.769
Efficiency
Days sales outstanding ▼-20.766Days payables outstanding ▼-251.117Operating cycle ▼-543.046Cash conversion cycle ▼-291.929Capex / Sales ▼-0.018R&D / Sales ▼-0.623
Balance-sheet strength
Current ratio ▲+2.033Net debt / EBITDA ▲+0.348Working capital ▲+453011000.000Invested capital ▲+783631000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-16 TransMedics Group (NASDAQ:TMDX) Shares Up 4.5% After Insider Buying Activity TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares shot up 4.5% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492
- 2026-09-15 2 Stocks Down 28% and 34% to Buy and Hold These companies'' sell-offs may have gone too far.
- 2026-09-14 TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-14 TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ), announces that K
- 2026-09-14 TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”).TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or.
- 2026-09-10 TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.
- 2026-09-07 Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
- 2026-09-03 TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investors On September 03, 2026, TransMedics Group Inc (TMDX) shares rose 3.2% to a current price of $86.98, which is situated within a 52-week range of $60.11 to $156.00
- 2026-09-03 Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure? TransMedics'' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
- 2026-09-03 Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report? TransMedics (TMDX) reported earnings 30 days ago. What''s next for the stock?